EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

New treatment for antibody-mediated rejection: interleukin-6 inhibitors

Byung Hwa Park iD, Ye Na Kim iD, Ho Sik Shin iD

Clinical Transplantation and Research · 2024

DOI: 10.4285/ctr.23.0069 ↗

At a glance

Übersichtsarbeit in Clinical Transplantation and Research, 2024. Written by Byung Hwa Park and 2 co-authors. Institution: Division of Nephrology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea. Cited 4 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Korean Society for Transplantation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Following kidney transplantation, antibody-mediated rejection (AMR) occurs when the antibodies of the immune system attack the transplanted organ, leading to damage of the kidney tissue. De novo human leukocyte antigen donor-specific antibodies (HLA-DSAs) play a key role in AMR. Current therapeutic approaches include intravenous immunoglobulin, anti-CD20 antibodies, and plasmapheresis. In cases resistant to treatment, proteasome inhibitors and C5 inhibitors may be employed. Nevertheless, a pressing need exists for new medications to improve transplant survival and reduce complications. In the context of AMR, interleukin (IL)-6 is instrumental in the development and maturation of B cells into plasma cells, which then produce HLA-DSAs targeting the allograft. IL-6 inhibitors are currently under investigation and show promise due to the essential role of IL-6 in the immune response; however, additional research is necessary.

Subjects

Author keywords

AntibodyInterleukin-6Kidney transplantationRejection

Authors and institutions

  • Division of Nephrology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea.
  • Transplantation Research Institute, Kosin University College of Medicine, Busan, Korea.

ORCID profiles: Byung Hwa Park, Ye Na Kim, Ho Sik Shin

Funding

  • Korean Society for Transplantation

Cite

APA

Park, B. H., Kim, Y. N., & Shin, H. S. (2024). New treatment for antibody-mediated rejection: interleukin-6 inhibitors. Clinical Transplantation and Research. https://doi.org/10.4285/ctr.23.0069

Vancouver

Park BH, Kim YN, Shin HS. New treatment for antibody-mediated rejection: interleukin-6 inhibitors. Clinical Transplantation and Research. 2024. doi:10.4285/ctr.23.0069

BibTeX
@article{Park2024,
  author = {Park, Byung Hwa and Kim, Ye Na and Shin, Ho Sik},
  title = {New treatment for antibody-mediated rejection: interleukin-6 inhibitors},
  journal = {Clinical Transplantation and Research},
  year = {2024},
  doi = {10.4285/ctr.23.0069}
}
Start for free →